Why The DTP Model Is A Win For Drug Manufacturers And Patients
Source: Life Science Leader
By Jay McHarg
Pre-COVID, typically DTP was only a distribution tactic for specialty medicines not generally sold in commercial pharmacies. But similar to telemedicine, once access was greatly diminished, alternatives started to emerge, including curbside pickup and in-town delivery.
VIEW THE MAGAZINE ARTICLE!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more